Wednesday, 15 August 2018 - 9:58
  • it
  • de
  • en
  • fr

Axovant Sciences

Alzheimer’s, Phase III trial of Lundbeck’s candidate fails

Lundbeck has reported the failure of a Phase III trial for its candidate to address Alzheimer’s disease. The drug has not reached, with neither dose, a result different from that obtained through the placebo. Lundbeck has conducted the research in…